Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/infdis/jiaa446 http://scihub22266oqcxt.onion/10.1093/infdis/jiaa446 32702095!7454684!32702095     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32702095&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Infect+Dis 2020 ; 222 (7): 1103-1107 Nephropedia Template TP {{tp|p=32702095|t=2020. Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy |pdf=|usr=}}{{32702095}} gab.com Text Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy JO: J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32702095 #FOAvip The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19. We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised patient. A man in his fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia. During two 10-day courses of remdesivir starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation. Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection. Combination therapy or longer treatment duration may be needed in immunocompromised patients. Twit Text FOAVip Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy ????J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32702095 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32702095 #FOAvip English Wikipedia <ref>{{Cite pmid|32702095}}</ref> Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy #MMPMID32702095 Helleberg M; Niemann CU; Moestrup KS; Kirk O; Lebech AM; Lane C; Lundgren J J Infect Dis 2020[Sep]; 222 (7): 1103-1107 PMID32702095show ga The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19. We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised patient. A man in his fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia. During two 10-day courses of remdesivir starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation. Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection. Combination therapy or longer treatment duration may be needed in immunocompromised patients. |Adenosine Monophosphate/*analogs & derivatives/therapeutic use[MESH] |Alanine/*analogs & derivatives/therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus/*drug effects[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/complications/*drug therapy/virology[MESH] |Fever/drug therapy/virology[MESH] |Humans[MESH] |Immunocompromised Host[MESH] |Leukemia, Lymphocytic, Chronic, B-Cell/*complications/drug therapy[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/complications/*drug therapy/virology[MESH] |SARS-CoV-2[MESH] |Severe Acute Respiratory Syndrome/*drug therapy/virology[MESH] |Time Factors[MESH]Persistent COVID-19 in an Immunocompromised Patient Temporarily Respon(epmc).pdf DeepDyve Pubget Overpricing